- Home
- FIVN vs TARS Comparison
FIVN vs TARS Comparison
Compare FIVN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- TARS
- Stock Information
- Founded
- FIVN 2001
- TARS 2016
- Country
- FIVN United States
- TARS United States
- Employees
- FIVN N/A
- TARS N/A
- Industry
- FIVN EDP Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- FIVN Technology
- TARS Health Care
- Exchange
- FIVN Nasdaq
- TARS Nasdaq
- Market Cap
- FIVN 2.1B
- TARS 1.7B
- IPO Year
- FIVN 2014
- TARS 2020
- Fundamental
- Price
- FIVN $22.80
- TARS $65.17
- Analyst Decision
- FIVN Buy
- TARS Strong Buy
- Analyst Count
- FIVN 19
- TARS 7
- Target Price
- FIVN $37.47
- TARS $67.14
- AVG Volume (30 Days)
- FIVN 1.9M
- TARS 748.0K
- Earning Date
- FIVN 11-06-2025
- TARS 11-12-2025
- Dividend Yield
- FIVN N/A
- TARS N/A
- EPS Growth
- FIVN N/A
- TARS N/A
- EPS
- FIVN 0.11
- TARS N/A
- Revenue
- FIVN $1,105,816,000.00
- TARS $295,521,000.00
- Revenue This Year
- FIVN $12.39
- TARS $137.28
- Revenue Next Year
- FIVN $9.48
- TARS $42.84
- P/E Ratio
- FIVN $209.70
- TARS N/A
- Revenue Growth
- FIVN 14.21
- TARS 254.45
- 52 Week Low
- FIVN $21.04
- TARS $31.99
- 52 Week High
- FIVN $49.90
- TARS $65.97
- Technical
- Relative Strength Index (RSI)
- FIVN 32.18
- TARS 74.43
- Support Level
- FIVN $24.66
- TARS $56.25
- Resistance Level
- FIVN $25.68
- TARS $59.78
- Average True Range (ATR)
- FIVN 0.99
- TARS 2.57
- MACD
- FIVN -0.35
- TARS 0.71
- Stochastic Oscillator
- FIVN 2.02
- TARS 95.35
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.